National Library of Energy BETA

Sample records for iort lort iort

  1. Setup verification and in vivo dosimetry during intraoperative radiation therapy (IORT) for prostate cancer

    SciTech Connect (OSTI)

    Soriani, Antonella; Landoni, Valeria; Marzi, Simona; Iaccarino, Giuseppe; Saracino, Biancamaria; Arcangeli, Giorgio; Benassi, Marcello

    2007-08-15

    The purpose of this study was to check the setup and dose delivered to the patients during intraoperative electron beam radiation therapy (IORT) for prostate cancer. Twenty eight patients underwent IORT after radical prostatectomy for prostate cancer by means of a dedicated mobile accelerator, Novac7 (by Hitesys, SpA, Italy). A 9 MeV electron beam at high dose per pulse was used. Eighteen patients received IORT at escalating doses of 16, 18, and 20 Gy at 85% isodose, six patients for each dose level. Further, ten patients received 20 Gy at 85% isodose. The electron applicator position was checked in all cases by means of two orthogonal images obtained with brilliance intensifier. Target and organ at risk doses were measured in vivo by a MOSFETs dosimetry system. MOSFETs and microMOSFET dosimeters were inserted into sterile catheters and directly positioned into the rectal lumen, for ten patients, and into the bladder to urethra anastomosis, in the last 14 cases. Verification at 0 deg. led to very few adjustments of setup while verifications at 90 deg. often suggested to bring the applicator closer to the target. In vivo dosimetry showed an absorbed dose into the rectum wall {<=}1% of the total dose. The average dose value inside the anastomosis, for the 12 patients analyzed, was 23.7 Gy with a standard deviation of {+-}7.6%, when the prescription was 20 Gy at 85% isodose. Using a C-arm mobile image intensifier, it is possible to assess if the positioning is correct and safe. Radio-opaque clips and liquid were necessary to obtain good visible images. In vivo MOSFETs dosimetry is feasible and reliable. A satisfactory agreement between measured and expected doses was found.

  2. Radiation protection measurements around a 12 MeV mobile dedicated IORT accelerator

    SciTech Connect (OSTI)

    Soriani, Antonella; Felici, Giuseppe; Fantini, Mario; Paolucci, Massimiliano; Borla, Oscar; Evangelisti, Giovanna; Benassi, Marcello; Strigari, Lidia

    2010-03-15

    Purpose: The aim of this study is to investigate radioprotection issues that must be addressed when dedicated accelerators for intraoperative radiotherapy (IORT) are used in operating rooms. Recently, a new version of a mobile IORT accelerator (LIAC Sordina SpA, Italy) with 12 MeV electron beam has been implemented. This energy is necessary in some specific pathology treatments to allow a better coverage of thick lesions. At an electron energy of 10 MeV, leakage and scattered x-ray radiation (stray radiation) coming from the accelerator device and patient must be considered. If the energy is greater than 10 MeV, the x-ray component will increase; however, the most meaningful change should be the addition of neutron background. Therefore, radiation exposure of personnel during the IORT procedure needs to be carefully evaluated. Methods: In this study, stray x-ray radiation was measured and characterized in a series of spherical projections by means of an ion chamber survey meter. To simulate the patient during all measurements, a polymethylmethacrylate (PMMA) slab phantom with volume 30x30x15 cm{sup 3} and density 1.19 g/cm{sup 3} was used. The PMMA phantom was placed along the central axis of the beam in order to absorb the electron beams and the tenth value layer (TVL) and half value layer (HVL) of scattered radiation (at 0 deg., 90 deg., and 180 deg. scattering angles) were also measured at 1 m of distance from the phantom center. Neutron measurements were performed using passive bubble dosimeters and a neutron probe, specially designed to evaluate ambient dose equivalent H{sup *}(10). Results: The x-ray equivalent dose measured at 1 m along the beam axis at 12 MeV was 260 {mu}Sv/Gy. The value measured at 1 m at 90 deg. scattering angle was 25 {mu}Sv/Gy. The HVL and TVL values were 1.1 and 3.5 cm of lead at 0 deg., and 0.4 and 1 cm at 90 deg., respectively. The highest equivalent dose of fast neutrons was found to be at the surface of the phantom on the central

  3. SU-E-T-548: Modeling of Breast IORT Using the Xoft 50 KV Brachytherapy Source and 316L Steel Rigid Shield

    SciTech Connect (OSTI)

    Burnside, W

    2015-06-15

    Purpose: Xoft provides a set of 316L Stainless Steel Rigid Shields to be used with their 50 kV X-ray source for Breast IORT treatments. Modeling the different shield sizes in MCNP provides information to help make clinical decisions for selecting the appropriate shield size. Methods: The Xoft Axxent 50 kV Electronic Brachytherapy System has several applications in radiation therapy, one of which is treating cancer of the breast intraoperatively by placing the miniaturized X-ray tube inside an applicator balloon that is expanded to fill the lumpectomy bed immediately following tumor removal. The ribs, lung, and muscular chest wall are all regions at risk to receive undesired dose during the treatment. A Xoft 316L Stainless Steel Rigid Shield can be placed between the intracostal muscles of the chest wall and the remaining breast tissue near the balloon to attenuate the beam and protect these organs. These shields are provided in 5 different sizes, and the effects on dose to the surrounding tissues vary with shield size. MCNP was used to model this environment and tally dose rate to certain regions of interest. Results: The average rib dose rate calculated using 0cm (i.e., no shield), 3cm, and 5cm diameter shields were 26.89, 15.43, and 8.91 Gy/hr respectively. The maximum dose rates within the rib reached 94.74 Gy/hr, 53.56 Gy/hr, and 31.44 Gy/hr for the 0cm, 3cm, and 5cm cases respectively. The shadowing effect caused by the steel shields was seen in the 3-D meshes and line profiles. Conclusion: This model predicts a higher dose rate to the underlying rib region with the 3cm shield compared to the 5cm shield; it may be useful to select the largest possible diameter when choosing a shield size for a particular IORT patient. The ability to attenuate the beam to reduce rib dose was also confirmed. Research sponsored by Xoft Inc, a subsidiary of iCAD.

  4. DOE/EIA-0202(84/3Q) Short-Term Energy Outlook

    Gasoline and Diesel Fuel Update (EIA)

    3Q) Short-Term Energy Outlook pn Quarterly Projections August 1984 Published: September 1984 Energy Information Administration Washington, D.C. t- jrt .ort lort .iort .iort iort iort iort ort Tt jm .erm -Term Term Term Term Term Term Term Term Term Term Term Term Term -Term -Term nergy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy ^nergy Outlook Outlook Outlook Outlook Outlook Outlook Outlook

  5. DOE/EIA-0202(85/2Q) Short-Term Energy Outlook

    Gasoline and Diesel Fuel Update (EIA)

    2Q) Short-Term Energy Outlook amm Quarterly Projections April 1985 Published: May 1985 Energy Information Administration Washington, D C t rt jrt .ort lort .iort iort iort lort '.ort ort .erm -Term -Term -Term -Term -Term -Term -Term -Term -Term -Term -Term -Term -Term -Term -Term xrm nergy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Outlook Outlook Outlook Outlook Outlook Outlook Outlook

  6. DOE/EIS-0200-SA-04 August

    Broader source: All U.S. Department of Energy (DOE) Office Webpages (Extended Search)

    1Q) Short-Term Energy Outlook Quarterly Projections February 1984 Published: March 1984 Energy Information Administration Washington, D.C. t rt jrt- .ort- iort- iort- .iort- iort- lort- <ort- ort Tt- .erm -Term -Term -Term -Term -Term -Term -Term -Term -Term -Term -Term Term Term .-Term -Term uergy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy ^nergy Outlook Outlook Outlook Outlook Outlook

  7. DOE/EIA-0202(84/1Q) Short-Term Energy Outlook Quarterly Projections

    Gasoline and Diesel Fuel Update (EIA)

    1Q) Short-Term Energy Outlook Quarterly Projections February 1984 Published: March 1984 Energy Information Administration Washington, D.C. t rt jrt- .ort- iort- iort- .iort- iort- lort- <ort- ort Tt- .erm -Term -Term -Term -Term -Term -Term -Term -Term -Term -Term -Term Term Term .-Term -Term uergy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy ^nergy Outlook Outlook Outlook Outlook Outlook

  8. DOE/EIA-0202(85/3Q) Short-Term Energy Outlook Quarterly Projections

    Gasoline and Diesel Fuel Update (EIA)

    3Q) Short-Term Energy Outlook Quarterly Projections July 1985 Published: August 1985 Energy Information Administration Washington, D C t rt jrt .ort lort iort iort iort iort '.ort ort Tt .-m .erm -Term -Term -Term -Term -Term -Term -Term -Term -Term -Term -Term -Term -Term -Term -Term Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy ^nergy Outlook Outlook Outlook Outlook Outlook Outlook Outlook

  9. DOE/EIA-0202(84/4Q) Short-Term Energy Outlook Quarterly Projections

    Gasoline and Diesel Fuel Update (EIA)

    4Q) Short-Term Energy Outlook Quarterly Projections October 1984 Published: November 1984 Energy Information Administration Washington, D.C. t rt jrt .ort lort iort lort iort lort \ort ort Tt .erm Term Term Term Term Term Term Term Term Term Term Term Term Term -Term -Term xrm nergy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy ^nergy Outlook Outlook Outlook Outlook Outlook Outlook Outlook

  10. Short-Term Energy Outlook

    Gasoline and Diesel Fuel Update (EIA)

    (83/3Q) Short-Term Energy Outlook iuarterly Projections August 1983 Energy Information Administration Washington, D.C. 20585 t rt jrt- .ort- iort- iort- iort- nort- lort- '.ort- ort- Tt- .-m .erm -Term -Term -Term -Term -Term -Term -Term -Term -Term -Term -Term -Term Term .-Term -Term xrm Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy ^nergy -OJ.UUK Outlook Outlook Outlook Outlook Outlook Outlook

  11. DOE/EIA-0202(87/4Q) Energy Information Administration Short-Term

    Gasoline and Diesel Fuel Update (EIA)

    4Q) Energy Information Administration Short-Term Energy Outlook Quarterly Projections October 1987 i- rt- jrt ort lort lort lort- iort- lort- ort- ort Tt- " t- . m erm Perm -Term -Term -Term -Term ,-Term -Term -Term -Term -Term -Term -Term -Term -Term -Term 71 e rrn TT1 "1 Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy "nergy -cry Outlook Outlook Outlook Outlook Outlook Outlook

  12. DOE/EIA-0202|83/2Q)-1 Short-Term Energy Outlook

    Gasoline and Diesel Fuel Update (EIA)

    |83/2Q)-1 Short-Term Energy Outlook Volume 1-Quarterly Projections May 1983 Energy Information Administration Washington, D.C. t rt jrt .ort lort iort iort lOrt iort '.ort- ort Tt . m .erm Term Term Term Term Term Term Term Term Term Term Term Term Term -Term -Term nergy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy ^nergy Outlook Outlook Outlook Outlook Outlook Outlook Outlook Outlook Outlook

  13. DOE/EIA-0202(84/2QH Short-Term Energy Outlook Quarterly Projections

    Gasoline and Diesel Fuel Update (EIA)

    2QH Short-Term Energy Outlook Quarterly Projections May 1984 Published: June 1984 Energy Information Administration Washington, D.C. t rt jrt .ort lort .iort .iort- iort- iort- '.ort- ort- .m .erm Term Term Term Term Term Term Term Term Term Term Term Term i-Term rTerm -Term xrm uergy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy ^nergy Outlook Outlook Outlook Outlook Outlook Outlook Outlook

  14. DOE/EIA-0202(87/1Q) Energy Information Administration Short-Term

    Gasoline and Diesel Fuel Update (EIA)

    7/1Q) Energy Information Administration Short-Term Energy Outlook Quarterly Projections January 1987 . m erm Term t-Term rt-Term jrt-Term ort-Term iort-Term lort-Term ion-Term lort-Term lort-Term ort-Term ort-Term rt-Term "t-Term -Term "rerm aergy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy "^nergy Outlook Outlook Outlook Outlook Outlook Outlook Outlook Outlook Outlook Outlook

  15. Intraoperative radiation therapy in recurrent ovarian cancer

    SciTech Connect (OSTI)

    Yap, O.W. Stephanie . E-mail: stbeast@stanford.edu; Kapp, Daniel S.; Teng, Nelson N.H.; Husain, Amreen

    2005-11-15

    Purpose: To evaluate disease outcomes and complications in patients with recurrent ovarian cancer treated with cytoreductive surgery and intraoperative radiation therapy (IORT). Methods and Materials: A retrospective study of 24 consecutive patients with ovarian carcinoma who underwent secondary cytoreduction and intraoperative radiation therapy at our institution between 1994 and 2002 was conducted. After optimal cytoreductive surgery, IORT was delivered with orthovoltage X-rays (200 kVp) using individually sized and beveled cone applications. Outcomes measures were local control of disease, progression-free interval, overall survival, and treatment-related complications. Results: Of these 24 patients, 22 were available for follow-up analysis. Additional treatment at the time of and after IORT included whole abdominopelvic radiation, 9; pelvic or locoregional radiation, 5; chemotherapy, 6; and no adjuvant treatment, 2. IORT doses ranged from 9-14 Gy (median, 12 Gy). The anatomic sites treated were pelvis (sidewalls, vaginal cuff, presacral area, anterior pubis), para-aortic and paracaval lymph node beds, inguinal region, or porta hepatitis. At a median follow-up of 24 months, 5 patients remain free of disease, whereas 17 patients have recurred, of whom 4 are alive with disease and 13 died from disease. Five patients recurred within the radiation fields for a locoregional relapse rate of 32% and 12 patients recurred at distant sites with a median time to recurrence of 13.7 months. Five-year overall survival was 22% with a median survival of 26 months from time of IORT. Nine patients (41%) experienced Grade 3 toxicities from their treatments. Conclusion: In carefully selected patients with locally recurrent ovarian cancer, combined IORT and tumor reductive surgery is reasonably tolerated and may contribute to achieving local control and disease palliation.

  16. Prospective Study of Local Control and Late Radiation Toxicity After Intraoperative Radiation Therapy Boost for Early Breast Cancer

    SciTech Connect (OSTI)

    Chang, David W.; Marvelde, Luc te; Chua, Boon H.

    2014-01-01

    Purpose: To report the local recurrence rate and late toxicity of intraoperative radiation therapy (IORT) boost to the tumor bed using the Intrabeam System followed by external-beam whole-breast irradiation (WBI) in women with early-stage breast cancer in a prospective single-institution study. Methods and Materials: Women with breast cancer ?3 cm were recruited between February 2003 and May 2005. After breast-conserving surgery, a single dose of 5 Gy IORT boost was delivered using 50-kV x-rays to a depth of 10 mm from the applicator surface. This was followed by WBI to a total dose of 50 Gy in 25 fractions. Patients were reviewed at regular, predefined intervals. Late toxicities were recorded using the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer Late Radiation Morbidity Scoring systems. Results: Fifty-five patients completed both IORT boost and external-beam WBI. Median follow-up was 3.3 years (range, 1.4-4.1 years). There was no reported locoregional recurrence or death. One patient developed distant metastases. Grade 2 and 3 subcutaneous fibrosis was detected in 29 (53%) and 8 patients (15%), respectively. Conclusions: The use of IORT as a tumor bed boost using kV x-rays in breast-conserving therapy was associated with good local control but a clinically significant rate of grade 2 and 3 subcutaneous fibrosis.

  17. Cosmetic Outcome and Seroma Formation After Breast-Conserving Surgery With Intraoperative Radiation Therapy Boost for Early Breast Cancer

    SciTech Connect (OSTI)

    Senthi, Sashendra; Link, Emma; Chua, Boon H.; University of Melbourne, Melbourne

    2012-10-01

    Purpose: To evaluate cosmetic outcome and its association with breast wound seroma after breast-conserving surgery (BCS) with targeted intraoperative radiation therapy (tIORT) boost for early breast cancer. Methods and Materials: An analysis of a single-arm prospective study of 55 patients with early breast cancer treated with BCS and tIORT boost followed by conventional whole breast radiation therapy (WBRT) between August 2003 and January 2006 was performed. A seroma was defined as a fluid collection at the primary tumor resection site identified clinically or radiologically. Cosmetic assessments using the European Organization for Research and Treatment of Cancer rating system were performed at baseline before BCS and 30 months after WBRT was completed. Results: Twenty-eight patients (51%) developed a seroma, with 18 patients (33%) requiring at least 1 aspiration. Tumor location was significantly associated with seroma formation (P=.001). Ten of 11 patients with an upper inner quadrant tumor developed a seroma. Excellent or good overall cosmetic outcome at 30 months was observed in 34 patients (62%, 95% confidence interval 53%-80%). Seroma formation was not associated with the overall cosmetic result (P=.54). Conclusion: BCS with tIORT boost followed by WBRT was associated with an acceptable cosmetic outcome. Seroma formation was not significantly associated with an adverse cosmetic outcome.

  18. Intraoperative Radiation Therapy in Early Breast Cancer Using a Linear Accelerator Outside of the Operative Suite: An “Image-Guided” Approach

    SciTech Connect (OSTI)

    Hanna, Samir Abdallah; Simões Dornellas de Barros, Alfredo Carlos; Martins de Andrade, Felipe Eduardo; Barbosa Bevilacqua, Jose Luiz; Morales Piato, José Roberto; Lopes Pelosi, Edilson; Martella, Eduardo; Fernandes da Silva, João Luis; Andrade Carvalho, Heloisa de

    2014-08-01

    Purpose: To present local control, complications, and cosmetic outcomes of intraoperative radiation therapy (IORT) for early breast cancer, as well as technical aspects related to the use of a nondedicated linear accelerator. Methods and Materials: This prospective trial began in May of 2004. Eligibility criteria were biopsy-proven breast-infiltrating ductal carcinoma, age >40 years, tumor <3 cm, and cN0. Exclusion criteria were in situ or lobular types, multicentricity, skin invasion, any contraindication for surgery and/or radiation therapy, sentinel lymph node involvement, metastasis, or another malignancy. Patients underwent classic quadrantectomy with intraoperative sentinel lymph node and margins evaluation. If both free, the patient was transferred from operative suite to linear accelerator room, and IORT was delivered (21 Gy). Primary endpoint: local recurrence (LR); secondary endpoints: toxicities and aesthetics. Quality assurance involved using a customized shield for chest wall protection, applying procedures to minimize infection caused by patient transportation, and using portal films to check collimator-shield alignment. Results: A total of 152 patients were included, with at least 1 year follow-up. Median age (range) was 58.3 (40-85.4) years, and median follow-up time was 50.7 (12-110.5) months. The likelihood of 5-year local recurrence was 3.7%. There were 3 deaths, 2 of which were cancer related. The Kaplan-Meier 5-year actuarial estimates of overall, disease-free, and local recurrence-free survivals were 97.8%, 92.5%, and 96.3%, respectively. The overall incidences of acute and late toxicities were 12.5% and 29.6%, respectively. Excellent, good, fair, and bad cosmetic results were observed in 76.9%, 15.8%, 4.3%, and 2.8% of patients, respectively. Most treatments were performed with a 5-cm collimator, and in 39.8% of the patients the electron-beam energy used was ?12 MeV. All patients underwent portal film evaluation, and the shielding was

  19. DOE/EIA-0202(85/1Q) Short-Term Energy Outlook Quarterly Projections

    Gasoline and Diesel Fuel Update (EIA)

    1Q) Short-Term Energy Outlook Quarterly Projections January 1985 Published: February 1985 Energy Information Administration Washington, D.C. t rt jrt .ort lort lort lort nort lort *.ort ort Tt .m .erm -Term -Term -Term -Term -Term -Term -Term -Term -Term -Term -Term -Term -Term -Term -Term uergy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy ^nergy Outlook Outlook Outlook Outlook Outlook Outlook

  20. DOE/EIA-0202(86/4Q) Energy Information Administration Short-Ter

    Gasoline and Diesel Fuel Update (EIA)

    6/4Q) Energy Information Administration Short-Ter m Energy Outlook Quarterly Projections October 1986 .m erm Term t-Term rt-Term jrt-Term ort-Term ion-Term lort-Term ion-Term lort-Term lort-Term ort-Term ort-Term -rt-Term -t-Term -Term iiergy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy Energy " Outlook Outlook Outlook Outlook Outlook Outlook Outlook Outlook Outlook Outlook Outlook Outlook Outlook

  1. SU-D-19A-03: Monte Carlo Investigation of the Mobetron to Perform Modulated Electron Beam Therapy

    SciTech Connect (OSTI)

    Emam, I; Eldib, A; Hosini, M; AlSaeed, E; Ma, C

    2014-06-01

    Purpose: Modulated electron radiotherapy (MERT) has been proposed as a mean of delivering conformal dose to shallow tumors while sparing distal structures and surrounding tissues. In intraoperative radiotherapy (IORT) utilizing Mobetron, an applicator is placed as closely as possible to the suspected cancerous tissues to be treated. In this study we investigate the characteristics of Mobetron electron beams collimated by an in-house prospective electron multileaf collimator (eMLC) and its feasibility for MERT. Methods: IntraOp Mobetron™ dedicated to perform radiotherapy during surgery was used in the study. It provides several energies (6, 9 and 12 MeV). Dosimetry measurements were performed to obtain percentage depth dose curves (PDD) and profiles for a 10-cm diameter applicator using the PTW MP3/XS 3D-scanning system and the semiflex ion chamber. MCBEAM/MCSIM Monte Carlo codes were used for the treatment head simulation and phantom dose calculation. The design of an electron beam collimation by an eMLC attached to the Mobetron head was also investigated using Monte Carlo simulations. Isodose distributions resulting from eMLC collimated beams were compared to that collimated using cutouts. The design for our Mobetron eMLC is based on our previous experiences with eMLCs designed for clinical linear accelerators. For Mobetron the eMLC is attached to the end of a spacer-mounted rectangular applicator at 50 cm SSD. Steel will be used as the leaf material because other materials would be toxic and will not be suitable for intraoperative applications. Results: Good agreement (within 2%) was achieved between measured and calculated PDD curves and profiles for all available energies. Dose distributiosn provided by the eMLC showed reasonable agreement (?3%/1mm) with those obtained by conventional cutouts. Conclusion: Monte Carlo simulations are capable of modeling Mobetron electron beams with a reliable accuracy. An eMLC attached to the Mobteron treatment head will allow